ARQT News and Press, Arcutis Biotherapeutics Inc. From 04/12/21

Roflumilast cream potential “Best in Class” topical PDE4 inhibitor Atopic dermatitis affects approximately 19 million patients in the U.S. The Company anticipates topline data in the second half of 2022 WESTLAKE VILLAGE, Calif., April 12, 2021 (GLOBE NEWSWIRE...

Arcutis Biotherapeutics ([[ARQT]] -1.5%) has named Scott Burrows as the company’s new CFO with effect from April 1, 2021.Announcing two additional appointments in the leadership team, Arcutis said Corey Padovano and Sean Brugger, have joined the company as Vice President of Sales and E...

Scott Burrows to succeed John Smither as Chief Financial Officer (CFO) upon Mr. Smither’s retirement Corey Padovano named Vice President of Sales Sean Brugger joins as Executive Director of Field Medical Affairs WESTLAKE VILLAGE, Calif., March 26, 2021 (GLOBE NE...

Arcutis Biotherapeutics (ARQT) announces enrollment of the first patient in a Phase 2a clinical trial evaluating ARQ-252 as a potential treatment for vitiligo, an auto-immune condition characterized by the loss of natural skin color or discolored patches on various pa...

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors Topline data anticipated second half 2023 Vitiligo affects approximately 1.3 million patients in the U.S. WESTLAKE VILLAGE, Calif., Mar...

WESTLAKE VILLAGE, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derm...

WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

Arcutis Biotherapeutics (ARQT): Q4 GAAP EPS of -$0.79 beats by $0.06.Strong financial position with over $470 million in cash, cash equivalents and marketable securities, including the proceeds from recent equity offering, providing cash runway into 2023.Press Release For further details se...

NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021 Positive Phase 3 data on topical roflumilast cream in plaque psoriasis reported in February Advancing topical roflumilast into Phase 3 programs for a...